LENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
LENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
LENSAR, Inc. (NASDAQ: LNSR), a leader in medical technology focused on femtosecond laser surgical solutions for cataracts, will release its fourth quarter and full year 2022 financial results on March 16, 2023, before the market opens.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
ORLANDO, Fla.--(BUSINESS WIRE)--
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2022 financial results will be released before market open on Thursday, March 16, 2023. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, March 16, 2023 to discuss the financial results and recent corporate highlights.
To participate by telephone, please dial (888) 886 7786 (Domestic) or 416 764 8658 (International). The conference ID number is 94867603. To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com. Following the live webcast, an archived version of the call will be available on the website.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of visually significant astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY® Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
